Welcome to our dedicated page for Viatris Ord Shs SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viatris Inc. (Nasdaq: VTRS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Viatris reports its financial performance, governance decisions and key corporate events as a global healthcare company that bridges generics and brands.
Viatris regularly files current reports on Form 8‑K to announce material events such as quarterly financial results, changes to bylaws, board appointments and other significant corporate actions. For example, the company has used Form 8‑K to report results for periods ended June 30 and September 30, 2025, and to disclose amendments to its bylaws related to proxy access and annual meeting timing. These filings often reference accompanying press releases that provide additional detail.
The company’s proxy statement on Schedule 14A (DEF 14A) offers insight into governance, board composition, executive compensation and strategic priorities. In its definitive proxy statement, Viatris discusses its enterprise-wide strategic review, capital return plans, pipeline progress and long-term shift toward a greater share of innovative brands, giving shareholders context for voting decisions and for evaluating management’s plans.
On this page, users can also monitor other SEC forms that may appear over time, such as annual and quarterly reports or any insider transaction reports on Form 4, as they become available. Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain technical language and help readers quickly identify topics such as revenue trends, strategic initiatives, bylaw changes and risk factors relevant to Viatris’ pharmaceutical preparation manufacturing business.
Filings are updated as they are released through EDGAR, allowing investors, analysts and other stakeholders to follow how Viatris communicates its financial condition, governance framework and strategic evolution through official regulatory channels.
Viatris Inc. presents its 2026 proxy statement and notice of annual meeting, combining a performance review with key voting items for shareholders. In 2025 the company generated $14.3 billion in total revenues, returned more than $1 billion to shareholders via dividends and buybacks, and completed 60 regional business development transactions, including acquiring Aculys Pharma in Japan.
The proxy highlights five positive Phase 3 data readouts, a pipeline that includes selatogrel and cenerimod, and a global footprint delivering more than 70 billion doses of medicine across over 165 countries and territories in 2025. It also describes an enterprise‑wide strategic review aimed at optimizing structure, resource allocation and efficiency to support long‑term growth.
Shareholders are asked to elect 13 directors, approve on a non‑binding basis 2025 compensation for named executive officers, and ratify Deloitte & Touche LLP as auditor for 2026. Governance themes include an independent Chair, 12 of 13 director nominees classified as independent, formation of a Strategic Review Committee, and continued board refreshment, with seven new directors appointed since December 2022. The filing notes strong shareholder engagement and that the 2025 Say‑on‑Pay proposal received approximately 95% support.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0% ownership of Viatris Inc. Common Stock as of the amendment. The filing explains an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries and business divisions from The Vanguard Group, Inc., and states those entities will report beneficial ownership separately.
The Schedule indicates Amount beneficially owned: 0 and sole and shared voting and dispositive powers: 0. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Viatris Inc officer Paul Campbell reported an open-market sale of 21,350 shares of common stock at a weighted average price of $13.2805 per share. After this sale, he directly holds 366,288 shares, plus 318 shares held indirectly through a 401(k) plan, indicating he retains a substantial position.
Viatris Inc Chief Commercial Officer Corinne Le Goff reported equity compensation activity centered on restricted stock units and related tax withholding. On March 6, 2026, 44,165 RSUs granted on March 6, 2025 vested and were settled into an equal number of Viatris common shares, along with 2,193 dividend equivalent units that also converted into common stock. To cover tax liabilities on these vestings, 20,561 common shares were withheld at $14.16 per share instead of being retained.
Le Goff also received a new grant of 88,984 RSUs, each representing one future share of common stock. According to the vesting schedule, 29,662 of these RSUs are scheduled to vest on March 6, 2027, and 29,661 are scheduled to vest on each of March 6, 2028 and March 6, 2029, while 44,164 RSUs from the 2025 grant remain scheduled to vest on March 6, 2027 and March 6, 2028. Following these transactions, Le Goff directly holds 83,214 shares of Viatris common stock.
Viatris Inc Chief Financial Officer Theodora Mistras reported several equity-compensation transactions. On March 6, 2026, 41,711 restricted stock units (RSUs) granted on March 6, 2025 vested and were settled into common shares, along with 2,070.6039 related dividend equivalent units (DEUs).
To cover tax obligations on these vestings, 23,067 and 1,146 common shares were withheld at $14.16 per share, so there was no open‑market sale. She also received a new grant of 86,017 RSUs that convert one‑for‑one into Viatris common stock.
Following these transactions, Mistras directly held 70,645 common shares, plus 86,017 RSUs and 4,141 DEUs. The new RSU grant vests in three annual installments: 28,673 units on March 6, 2027 and 28,672 units on each of March 6, 2028 and March 6, 2029.
Maletta Matthew Joseph reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc reported that Chief Legal Officer Matthew Joseph Maletta received a grant of 59,323 restricted stock units on March 6, 2026. Each RSU represents one share of Viatris common stock. The award vests in three annual tranches: 19,775 RSUs on March 6, 2027 and 19,774 RSUs on each of March 6, 2028 and March 6, 2029. Following this compensation-related grant, Maletta holds 59,323 RSUs directly.
Viatris Inc director Michael Severino reported equity compensation-related transactions in company stock. On March 6, 2026, 25,112 restricted stock units and 918.455 dividend equivalent units vested and were converted into an equal number of Common Stock shares, leaving him with 26,031 common shares directly held after these acquisitions. The same day, he also received a new award of 15,890 restricted stock units, which are scheduled to vest on March 6, 2027. All activity reflects derivative exercises and grants at a price of $0.00 per unit under the Viatris Inc. 2020 Stock Incentive Plan, with no open-market purchases or sales disclosed.
Viatris Inc executive Andrew Enrietti reported routine equity compensation activity involving restricted stock units (RSUs), dividend equivalent units (DEUs) and related tax withholding. On March 6, 2026, 19,169 RSUs granted on March 6, 2025 vested and were exercised into 19,169 shares of common stock, and 951.6215 DEUs were likewise exercised into 951.6215 shares.
To cover tax liabilities from these vestings, 8,337 and 415 shares of common stock were withheld at $14.16 per share, which is a non‑market disposition rather than an open‑market sale. After these transactions, Enrietti directly held 219,677 shares of Viatris common stock.
He also received a new award of 60,435 RSUs on March 6, 2026, each representing one share of common stock, scheduled to vest in three equal installments of 20,145 RSUs on March 6 of 2027, 2028 and 2029, in addition to remaining unvested RSUs and associated DEUs from the 2025 grant.